Our Portfolio
We have a growing portfolio aimed at addressing unmet medical needs. Globally, we are focused on developing and delivering vaccines across these disease areas:
Smallpox and Ebola*
Strengthening biosecurity and global preparedness
Rabies, TBE & Monkeypox
Help protect every day, help protect whilst traveling
Equine encephalitis, RSV
Addressing unmet medical need
COVID-19
Advancing the development of a next-generation vaccine
Grey box indicates products in development, not yet approved.
COVID-19, coronovirus disease 2019; RSV, Respiratory Syncytial Virus; TBE, tick-borne encephalitis.
*in collaboration with Janssen
Our History
Bavarian Nordic was founded in 1994, with a vision to help improve and save lives through the development and manufacturing of innovative life-saving vaccine technologies.
Some of Our Key Milestones…
Whilst proud of our achievements in vaccine development over the past 25 years, we are focused on the future. Right now, we are working on bringing patients around the globe an even greater degree of protection from infectious diseases.
Our Vision For Infectious Diseases
We aspire to help save lives by unlocking the power of the immune system. Our focus is always on the patient which is why we continue to provide prescribers and healthcare professionals with support for medical and disease education to help improve awareness. This portal for healthcare professionals will offer the latest product information, resources, learning modules and content from infectious disease specialists around the globe.
With our recent acquisition of well-known and trusted vaccine products from GSK, we are committed to delivering trusted, transparent and reliable vaccine supply.